Riskpilot← Back to searchSign inGet full accessÖrebro Neurofys AB
ABActiveOrg 5591681266Fjärde Tvärgatan 9Medical specialists activities · NACE 8622Est. 20180 employees
Revenue 2025
SEK 496K
-27% vs 2024
EBITDA margin
89.7%
-20% vs 2024
Equity ratio
73.7%
Financial strength
Net profit 2025
SEK 371K
-20% vs 2024
| Revenue | SEK 496K | -27% |
| EBITDA | SEK 445K | -20% |
| Net profit | SEK 371K | -20% |
| Total assets | SEK 974K | +29% |
| Equity | SEK 718K | +29% |
| Employees | 0 | — |
Legal name
Örebro Neurofys AB
Org number
5591681266
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
15 augusti 2018
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Högspecialiserad konsultation inom Klinisk Neurofysiologi.
Address
Fjärde Tvärgatan 9
Email
hfmu1202@yahoo.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 52 | 677 | 496 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −4 | −4 | 30 | 554 | 445 |
| Depreciation & amort. | −0 | — | −0 | −0 | −0 |
| EBIT | −4 | −4 | 30 | 554 | 445 |
| Net financials | — | 0 | — | 29 | 22 |
| Profit before tax | −4 | −4 | 30 | 583 | 467 |
| Tax | −0 | — | −3 | −120 | −96 |
| Net profit | −4 | −4 | 27 | 463 | 371 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 76 | 76 | 111 | 754 | 974 |
| Equity | 70 | 66 | 94 | 557 | 718 |
| Long-term debt | 0 | — | 0 | 0 | 0 |
| Short-term debt | 6 | 9 | 18 | 197 | 256 |
| Total debt | 6 | 9 | 18 | 197 | 256 |
EBITDA margin
89.7%
This company
15.8%
Market median
+468% vs market
20212025
Equity ratio
73.7%
This company
38.2%
Market median
+93% vs market
20212025
Return on equity
51.7%
This company
18.4%
Market median
+181% vs market
20212025
Net profit margin
74.8%
This company
8.1%
Market median
+823% vs market
20212025
Asset turnover
0.51×
This company
1.12×
Market median
-54% vs market
20212025
Debt / equity
0.36×
This company
0.62×
Market median
+42% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2021 | |
| Former (2) | ||
| Board of Directors | 2023 – 2023 | |
| Deputy Board Member | 2023 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Örebro Neurofys AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dmitri Buzarov | Board of Directors | 0 companies |
| Omaima Adnan Hassoon Al-Zubaidi | Deputy Board Member | 0 companies |
| Hamid Fakher | Board of Directors | 0 companies |
| Natalia Markova | Deputy Board Member | 0 companies |